Curanex Pharmaceuticals Stock Soars 56.32% After Key IND Milestone
- Key Milestone Achieved: Curanex Pharmaceuticals announced the completion of a GMP-compliant pilot-scale batch of its lead botanical drug candidate, Phyto-N, driving a 56.32% increase in after-hours trading to $0.49, reflecting strong market confidence in its future potential.
- IND Submission Plans: The company aims to submit an Investigational New Drug application for ulcerative colitis, affecting approximately 5 million patients globally, targeted for the fourth quarter of 2026, indicating a strategic focus in the chronic inflammatory bowel disease sector.
- Clinical Research Advancement: CEO Jun Liu stated that GLP toxicology and pharmacokinetic studies are underway, with clinical trials planned in Australia to further validate the drug's safety and efficacy, showcasing the company's commitment to advancing its pipeline.
- Market Performance Analysis: Despite a market capitalization of $8.73 million and a 92.15% decline in stock price over the past 12 months, recent positive developments may present potential rebound opportunities for investors, necessitating close monitoring for signs of recovery.
Trade with 70% Backtested Accuracy
Analyst Views on CURX
About CURX
About the author

- Key Milestone Achieved: Curanex Pharmaceuticals announced the completion of a GMP-compliant pilot-scale batch of its lead botanical drug candidate, Phyto-N, driving a 56.32% increase in after-hours trading to $0.49, reflecting strong market confidence in its future potential.
- IND Submission Plans: The company aims to submit an Investigational New Drug application for ulcerative colitis, affecting approximately 5 million patients globally, targeted for the fourth quarter of 2026, indicating a strategic focus in the chronic inflammatory bowel disease sector.
- Clinical Research Advancement: CEO Jun Liu stated that GLP toxicology and pharmacokinetic studies are underway, with clinical trials planned in Australia to further validate the drug's safety and efficacy, showcasing the company's commitment to advancing its pipeline.
- Market Performance Analysis: Despite a market capitalization of $8.73 million and a 92.15% decline in stock price over the past 12 months, recent positive developments may present potential rebound opportunities for investors, necessitating close monitoring for signs of recovery.
Bullish Earnings Report: Bullish (BLSH) shares surged 12.3% in pre-market trading after reporting a profit of 93 cents per share for Q2, a significant improvement from a loss of $1.03 per share a year ago, with revenues rising to $58.63 million.
Notable Gainers: 89bio, Inc. (ETNB) saw an 82.9% increase due to an acquisition by Roche, while other stocks like Psyence Biomedical Ltd (PBM) and Aptevo Therapeutics Inc (APVO) also experienced significant gains in pre-market trading.
Major Losers: Wheeler Real Estate Investment Trust, Inc. (WHLR) dropped 23.1% following a reverse stock split announcement, and other companies like Office Properties Income Trust (OPI) and Educational Development Corporation (EDUC) also faced declines in pre-market trading.
Market Overview: The pre-market trading session showed a mix of sharp gains and losses among various stocks, reflecting a volatile market environment influenced by earnings reports and corporate announcements.







